F-Arag

F-Arag

SCHEMBL16656455

Nc1nc2c(ncn2C2OC(CO)C(O)C2F)c(=O)[nH]1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.64
ADORA3 P0DMS8 1/20 0.64
ADORA2A P29274 1/20 0.64
ADORA1 P30542 1/20 0.64
ADRA1A P35348 1/20 0.64
PDE4D Q08499 1/20 0.64
PDE3A Q14432 1/20 0.64
HPGD P15428 2/20 0.62
HINT1 P49773 4/20 0.57
NT5E P21589 2/20 0.57
PNP P00491 2/20 0.56
CD99 P14209 1/20 0.55
GSK3A P49840 2/20 0.54
RPS6KA3 P51812 2/20 0.54
MAPK14 Q16539 2/20 0.54
LMNA P02545 1/20 0.53
HIF1A Q16665 1/20 0.53
PAX8 Q06710 1/20 0.53
TGM2 P21980 1/20 0.53
STING1 Q86WV6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
F-Arag SCHEMBL313467 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag SCHEMBL9489885 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag SCHEMBL12150772 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag SCHEMBL14163604 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag SCHEMBL12300492 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag SCHEMBL236684 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag SCHEMBL35286 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag SCHEMBL20581034 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag SCHEMBL21625251 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A
F-Arag F-18 SCHEMBL29373858 1.00 PDE2A (0.64) PDE2AADORA3ADORA2AADORA1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230309833-A1 METHODS AND MATERIALS FOR USING [18F]-F-ARAG IN CARDIAC IMAGING CELLSIGHT TECHNOLOGIES INC. (US) 2023-10-05 US disclosed
US-20150118157-A1 Compounds and Methods of Making Compounds THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2015-04-30 US disclosed
US-9011817-B2 Compounds and methods of making compounds THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2015-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150118157-A1 Compounds and Methods of Making Compounds MCL1, TOP2B, TOP1 PDE2A 666/4885ADORA3 1555/4885ADORA2A 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.